<DOC>
	<DOC>NCT01901107</DOC>
	<brief_summary>The purpose of this survey is to evaluate the safety and efficacy of long-term use of KiklinÂ® Capsules in actual clinical settings.</brief_summary>
	<brief_title>Post-marketing Surveillance of Kiklin Capsules in Hemodialysis Patients</brief_title>
	<detailed_description>Bixalomer is administered at initial oral dosage of 500 mg three times a day just before a meal. The dosage can be adjusted based on symptoms and serum phosphorus level.</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<criteria>Chronic renal failure patients with hyperphosphataemia receiving hemodialysis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hemodialysis</keyword>
	<keyword>CKD (chronic kidney disease)</keyword>
	<keyword>ASP1585</keyword>
	<keyword>Hyperphosphatemia</keyword>
</DOC>